ABA therapy, 37, 38–9
abnormal facial movements, in pediatric narcolepsy with cataplexy, 30
Abnormal Involuntary Movement Scale (AIMS), 119
abnormal/disorganized motor behavior, 107
abuse, 45, 46, 70, 79
acetylcholine, 117, 155
acrophobia, 42
acute stress disorder, 45
Adderall (amphetamine salts), 72
adenotonsillectomy, 28, 30
ADHD in PWS, 68–75
aggression, treating with antidepressant medications, 121
agitation and aggression in PWS, 77–88
Amon’s case, 3
caregiver note, 88
examples, 77
intellectual development vs age, 82–3
internalizing vs externalizing, 81–2
management
non-pharmacological, 83–5
pharmacological, 86–7
operant conditioning, 80–1
potential triggers, 79
prevalence, 77
reactive and proactive aggression, 80
agonophilia, 42
akathisia, 118
alexithymia, 90
Alisha, case history
aggressive behavior, 45
anxiety, 45–6
PTSD, 46
aologia, 108
alpha-2 agonists ADHD and, 73
autism and, 39
managing aggression with, 86
managing picking behavior with, 62
mechanism of action, 134
see also individual drugs.
alprazolam, 31, 52, 110
amenorrhea, 119
American Association for Retired People (AARP), 8
American Psychiatric Association, 21
American Psychological Association, 21
anterior cingulate cortex (ACC), 160–1, 163
anterior thalamic radiation, 161–2
antibiotics, 111, 130, 147
anticholinergics, 54
commonly implicated in delirium, 110
anticonvulsants, managing picking behavior with, 62
antidepressant medications, 120–5
ADHD and, 74
adverse effects, 124–5
behavioral activation, 124–5
discontinuation syndrome, 125
serotonin syndrome, 125
suicidality, 96, 125
tyramine reaction, 122, 125
bupropion, 124
delirium and, 110
managing aggression with, 87
mirtazapine, 53, 124
monoamine oxidase inhibitors (MAOIs), 122
residential placement, 4
school experiences, 2, 4
amoamine, 122
anabolism, 156
anandamide (arachidonoyl ethanolamide), 164
anxiety, 45
Angelman syndrome, schizophrenia and, 103
anger, 79, 88, 91, 110
anger outbursts, 116, 156
anhedonia (lack of interest in activities), 91, 108
Anna, case history, depressive disorder, 95
antecedent-behavior-consequence (ABC) model of CBT, 50
anterior cingulate cortex (ACC), 160–1, 163
anterior thalamic radiation, 161–2
antibiotics, 111, 130, 147
anticholinergics, 54
commonly implicated in delirium, 110
anticonvulsants, managing picking behavior with, 62
antidepressant medications, 120–5
ADHD and, 74
adverse effects, 124–5
behavioral activation, 124–5
discontinuation syndrome, 125
serotonin syndrome, 125
suicidality, 96, 125
tyramine reaction, 122, 125
bupropion, 124
delirium and, 110
managing aggression with, 87
mirtazapine, 53, 124
monoamine oxidase inhibitors (MAOIs), 122
Index

overdose, 110, 125
reasons for prescription in PWS, 120
serotonin norepinephrine reuptake inhibitors (SNRIs), 123
serotonin reuptake inhibitors (SRIs), 123
side effects, 122, 124–5
summary of dosages and side-effects, 126
symptoms treated by, 125
trazodone, 124
treatment of sleep disturbances with, 31
trials, 31
tricyclic antidepressants (TCAs), 122
overdose, 53, 122
antipsychotic medications, 117–121
classifications, 117
managing aggression with, 87
managing anxiety with, 54
managing behavioral problems with, 117
managing picking behavior with, 62
mechanism of action, 117
neurotransmitter receptor affinities, 117
overdose, 120
recommendations for use in PWS, 118
side effects, 38, 117, 118–20
extrapyramidal symptoms with, 118–19
hyperprolactinemia, 119
metabolic syndrome, 119
neuroleptic malignant syndrome, 120
QTc prolongation, 119
summary of dosages and, 121
withdrawal
dyskinesia, 119
utilization in PWS, 120
anti-seizure medications, potential role in managing anxiety, 54
anxiety
anxiety disorders, 41–3
agoraphobia, 42
generalized anxiety disorder (GAD), 42–3
panic disorder, 42
selective mutism, 42
separation anxiety disorder, 41
social anxiety disorder, 42
specific phobia, 42
definition, 41
DSM-5 description, 41
hallucinations and, 106
obsessive-compulsive and related disorders, 43–4
prevalence in the general population, 41
trauma and stress-related disorders, 44–6
neurotransmitters and, 163
overdose, 120
reasons for prescription in PWS, 120
serotonin norepinephrine reuptake inhibitors (SNRIs), 123
social anxiety disorder, 42
specific phobia, 42
definition, 41
DSM-5 description, 41
hallucinations and, 106
obsessive-compulsive and related disorders, 43–4
prevalence in the general population, 41
trauma and stress-related disorders, 44–6
treating with serotonin and, 163
SNRIs and, 74
SRIs and, 123
stimulant medications and, 71, 72, 134
see also obesity; weight gain.

applied behavioral analysis (ABA) therapy, 20, 38
2-arachidonoyl glycerol (2-AG), 164
arachnophobia, 42
aripiprazole, 38, 87, 118, 119
armodafinil, 134
asociality, 108
Asperger’s syndrome, 39
assessment, 1, 21, 79
atomoxetine, 63, 73, 123, 134
attention-deficit/hyperactivity disorder (ADHD), 68–75
commonly associated symptoms, 69
differentiating between mood disorders and, 70
dysfunction and depression and, 65
heritability, 70
impulsivity and, 163
management, pharmacological, 39, 123, 134
multimodal treatment trial, 71
myths surrounding, 70
overview, 68–70
presentation and classification, 68
prevalence in PWS, 68
prevalence in the general population and in children with intellectual disabilities, 1, 68
white matter abnormalities and, 162
see also ADHD in PWS.
atypical depression, 92–3, 122
auditory hallucinations, 105
autism
beneficial medications, 38
characteristics, 34
178 Index

autism (cont.)
depression and, 91
difficulty expressing mood and, 90
possible genetic link with PWS, 34
prevalence in general population, 36
prevalence in PWS, 34
autism in PWS, 34–9
caregiver note, 39
Jackson’s case, 37
management
non-pharmacological, 38
pharmacological, 38–9
recognizing, 37
autism spectrum disorder (ASD), 34
DSM-5 criteria, 35–35
overlapping with PWS symptoms, 35–6
range, 39
autistic spectrum disorder (ASD), distinguishing from psychosis, 107

bariatric surgery, 28
bedwetting, 122
Peter’s case, 43
pharmacological management, 53, 122
behavioral activation, antidepressant medications and, 124–5
behavioral issues in PWS, 58–65
behavioral health providers, 19–21
caregiver note, 65
elopement (running away), 64–5
hoarding, 62–4
picking (excitation disorder), 58–9
behavioral pediatricians, 19
behavioral problems
managing with antipsychotic medications, 117
managing with oxytocin, 135
related to anxiety, 43
symptomatic of PWS, 1
behavioral therapy, ADHD and, 71, 75
benzodiazepines, 132–4
addictive potential, 52
adverse effects, 31, 52

CNS depression, 133
delirium, 110
dependence, 133
paradoxical agitation, 52, 134
tolerance, 133
withdrawal, 133
disinhibition and, 87
examples, 52
half-life, 132
managing aggression with, 87
managing anxiety with, 52, 132
managing sleep disturbances with, 31
mechanism of action, 132
overdose, 52
potential withdrawal reaction, 52
summary of dose range and half life, 133
benztropine, 119
biopsychosocial holistic approach, 1
bipolar disorder
ADHD vs, 70
distinguishing depression from, 120
importance of correct diagnosis, 127
risk in PWS, 52
white matter abnormalities and, 162
bipolar disorders in PWS, 98–9
caregiver note, 100
management
non-pharmacological, 100
pharmacological, 100, 128
Pete’s case, 98
body dysmorphic disorder, 44
brain
ADHD and, 70
areas affected in PWS, 171
grey matter abnormalities, 160
hypothalamus, 157–8
neurotransmitter abnormalities, 162–5
roles of white and grey matter, 154–5
structure of, 154
white matter abnormalities, 160–2
bright light therapy, 93
bromocriptine, 120
bupropion, 74, 124, 174
burnout, concept of, 10
buspirone, 53, 135
cannabinoids, 54, 87, 135, 162, 164
carbamazepine, 62, 129, 130, 136, 136
carbetocin, 54, 135
caregiver burden
agitation/aggression and, 77
assessing the caregiver for signs and symptoms of, 14
average time spent providing care, 9
causes, 14–15
caregiving community and, 11
concept of, 8–9
control and, 10–11
demographic and psychosocial risk factors, 9, 15
experience of, 14–15
fairness and, 11
financial aspect of caregiving work, 9
interest preoccupation and, 47
potential depressive impact on patient, 92
potential impact, 9
reducing the risks, 11–14
risk for burnout, 9–11
support recommendations, 173
values and, 11
workload mismatch and, 10
caregivers
agitation and aggression in PWS and, 78–9
educational role, 22
potential benefits of caregiving, 8
US statistics, 8
case studies
ADHD, 68
aggressive behavior, 3, 45
Alisha, 45–6
see also Alisha, case history.
Amon, 2–5
see also Amon, case history.
Anna, 95
anxiety, 43, 45–6, 47
disorganized thinking (formal thought disorder), 106–7
disorganized/abnormal motor behavior, 107
disruptive mood dysregulation disorder (DMDD), 97
distraction, value of in managing anxiety, 51
dopamine, 104, 155, 171
ADHD and, 70
antidepressant medications and, 122, 123
antipsychotic medications and, 117, 118, 119
excitatory nature, 155
interaction with serotonin, 155
psychosis and, 104
receptor types, 155
drug-drug interactions, 120, 135–138
DSM-5
anxiety, 41
autism spectrum disorder (ASD), 35–36
narcolepsy, 29
psychosis, 104
psychotic disorders, 108–11
duloxetine, 123
dysphoria, stimulant medications and, 72, 87
dystonia, 118
dystonic muscle spasms, 117
echolalia, 107
EDS, see excessive daytime sleepiness (hypersomnia),
effective food security, 12, 49
effective semantic cognition, 162
electroconvulsive therapy (ECT), 96
Eli, case history, depressive disorder, 96
elopement (running away)
case studies, 64
management of, 65
prevalence and potential triggers in PWS, 64
emotional behavioral functions, hypothalamic dysfunction and, 158
emotional exhaustion, 10, 15
emotions and behavior, Sonny’s case, 149–50
endocannabinoids, 164
diabetes functions, hypothalamic dysfunction and, 158
enuresis, see also bedwetting, 53, 122
Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD), 27
escalotram, 52, 87, 123
Ethan, case history, cycloid psychosis, 111–13
excessive daytime sleepiness (hypersomnia)
ADHD and, 69, 70
agitation/aggression in PWS and, 79
caregiver note, 31
definition, 27
depressive disorders and, 91, 132
JS’s case, 26
management non-pharmacological, 30 pharmacological, 31, 71, 134
multiple sleep latency test (MSLT) in evaluation of, 28
OSA and, 26
prevalence in PWS, 27
prevalence in US teens, 27
primary vs secondary disorders, 27
excessive familiarity with strangers, 42
excoriation disorder, see picking (excoriation disorder).
exercise involving family members in, 12
value for PWS patients, 12–13
extrapyramidal symptoms (EPS), risk of antipsychotic medication for, 118–19
eyelash pulling, 59
eyes, oculogyric crisis, 3, 118
facial and masticatory muscle contractions, 30
familiarity with strangers, excessive, 42
family psychoeducation, 114
feelings, talking about, 51
fight or flight response, 41, 53
fluoxetine, 52, 63, 87, 123, 135
fluvoxamine, 123, 125
Focalin (dexmethylphenidate), 72
Food and Drug Association (FDA), 74, 117, 134, 163
food security, 12, 49, 78
food-seeking behavior, see also hyperphagia, 2, 26, 157
forceps major, 161–2
forceps minor, 161
Foundation for Prader-Willi Research, 13
fractional anisotropy (FA), 161
frequent tongue protrusions, 30
frustration, poor tolerance of, 47–8, 53–4
gabapentin, 54
gait unsteadiness, 30
gambling, 48
gamma-aminobutyric acid (GABA), 42
GABA analogs, 129
gameX, 52, 63, 87, 123, 135
galea, 155
gray matter
glycine, 155
glutamate, 127, 155
Ginkgo, 125
glaucoma, 155
γ-glutamyltransferase, 185
γ-aminobutyric acid (GABA), 127, 155
GABA agonists, 129
GABA analogs, 129
gastroparesis, 149
gastropareis, 149
generalized anxiety disorder (GAD), 42–3
genetic causes of neurobehavioral problems, 156–7
Ginkgo, 125
glutamate, 127, 155
glucose, 155
grey matter abnormalities, 160
role of, 154–5
group therapy, 38
growth hormone treatment, 5
growth hormone treatment, Peter’s case, 43
guanfacine, 53, 62, 73, 86, 134
guanfacine extended-release (GXR), 39, 58, 62, 134, 174
gustatory hallucinations, 106
gynecomastia, 119
habit-based learning system, 167, 172
hallucinations, 105–6
brief psychotic disorder and, 111
cycloid psychosis and, 111, 113, 114
delirium and, 110
psychosis and, 104
PWS symptom, 104
schizoaffective disorder and, 109
schizophrenia and, 108
haloperidol, 54, 136
heart disease, stimulant medications and, 72
hemophilia, 42
high dose vitamin E, 119
hippocampus, 158, 160
hoarding management non-pharmacological, 63 pharmacological, 63–4 prevalence in PWS, 44 hydroxyzine, 54 hyperbaric oxygen treatment, 58 hyperlipidemia, 117 hyperphagia abnormal ACC function and, 160 agitation/aggression and, 78 Amon’s case, 2, 3, 26, 150–1 cannabinoid exploration, 87, 164 consequences, 1 Dykens Hyperphagia Questionnaire, 129 elopement behavior and, 64 food-hoarding and, 63 genetic basis, 156 JS’S case, 26 management improvement in, 140 pharmacological, 54, 71, 72, 135 meal planning and, 12 medical school emphasis, 1, 145 neurobiological basis, 172 obesity and, 1, 30 psychosis and, 108, 114 Sonny’s case, 150–1 stimulant medications and, 71, 72 hyperprolactinemia, risks of antipsychotic medication for, 119 hyporsomnia, see excessive daytime sleepiness (hyporsomnia)
hypnagogic hallucinations, 106 hypnopompic hallucinations, 106 hypogonadism, 119, 156, 158 hypothalamus dysfunction of, central role in PWS, 157–8, 167, 171 functions and associated abnormalities, 159 hyperphagia and, 156 picking behavior and, 156 hypothyroidism, depression and, 120 hypotonia, see also low muscle tone, 26, 27, 145, 156–7 impulsivity ADHD and, 69, 70, 71, 74, 163 aggression in PWS and, 86 benzodiazepines and, 52 differentiating anxiety from, 48 DMDD and, 97 management, pharmacological, 62, 65, 129, 134 response monitoring and, 165, 172 response perseveration and, 48 serotonin abnormalities and, 163 threats to self-harm and, 93 underlying mechanism of anxiety, 48–9 inferior frontal gyrus, 162 inferior frontal gyrus, ADHD and, 70 inferior fronto-occipital fasciculus, 161, 162 inferior longitudinal fasciculus, 161 inferior temporal lobes, 167 inflexibility, 47, 160 serotonin abnormalities and, 164 informal caregiving, US statistics, 8 insomnia depressive disorders and, 91 discontinuation syndrome and, 125 management, 31, 122, 124, 129, 132 medication-induced, 72 SNRs and, 123 insula, 160, 167 insulin resistance, Amon’s case, 4 interest preoccupation, 35, 47 interest preoccupation, JC’s case, 47 International Prader-Willi Syndrome Organization, 21 irritability ADHD and, 70 Amon’s case, 3 anxiety disorders and, 43, 46 bipolar disorder and, 98 caregiver note, 100 COVID-19 mitigations and, 54 delirium and, 110 depressive disorders and, 91–2 DMDD and, 97 dysphoria and, 72 genetic basis, 156 management, 86, 121, 134, 174 persistent depressive disorder and, 92 poor response monitoring and, 167, 172 PTSD and, 45 self-harm, 93 SIADH and, 132 sleep disturbances and, 79 treating with antidepressant medications, 121 Jackson, case history, autism, 37 JC, case history anxiety, 47 interest preoccupation, 47 journaling, value for reducing risk of caregiver burden and burnout, 13
Index

182

JS, case history
behavior and sleep
disturbances, 26
CPAP treatment and weight
loss program, 28
diagnosis, 29–30
evaluation and referral, 27
family history of OSA, 27
in-laboratory nocturnal
polysomnogram, 28,
sleep architecture, 28
see also sleep disturbances;
sleep-disordered breathing.

ketamine, 87

lamotrigine, 62, 100, 128, 130
leaden paralysis, depressive
disorders and, 92, 122
learned oppositional
behavior, 80
licensed clinical social
workers, 21
lisdexamfetamine, 72
lithium, 96, 100, 114, 128,
136
locus coeruleus, 156, 162, 171
lorazepam, 31, 52, 87, 110, 114
lorcaserin, 163
low muscle tone, 2, 37, 69, 70
lurasidone, 118, 174

Magel 2 gene, 156
major depressive disorder
(MDD), 91–2
mammalian target of
rapamycin
(mTOR), 156
mania, stimulant medications
and, 72
manic episodes, 90
mask-wearing, anxiety-
reducing strategies, 50
maternal uniparental disomy
(mUPD)
prescription of psychotropic
medication and, 27
psychosis and, 103
meal planning, involving
family members in, 12
medial prefrontal cortex, 163
medications, drug-drug
interaction
considerations, 120,
135–138
melanin-concentrating
hormone, 157
mental health issues, agitation/
aggression in PWS
and, 79
mental health providers
behavioral health providers,
19–21
centers of excellence, 24
changing providers, 23–4
choosing a provider, 21
considerations for
caregivers, 25
establishing relationships
with, 18–25
ethical principles, 23
finding the right provider,
21–2, 25
increased recognition of role
in PWS care, 18
multidisciplinary model, 24
prescribing providers, 19
psychiatrists, 19
what to look for, 22
mentalization, white matter
abnormalities and, 162
meperidine, 125
metabolic syndrome, risk of
antipsychotic
medications for, 119
metformin, 5
methylphenidate, 72
micrognathia, 27
midazolam, 87
mindfulness, 173
managing aggression
with, 84
managing anxiety with, 51
managing bipolar disorders
with, 100
managing depressive
disorders with, 96
value for reducing risk of
caregiver burden and
burnout, 13
mirtazapine, 53, 124
mistreatment, 46, 79
modafinil, 31, 134
model-based reinforcement
learning, 165, 172
Modified Overt Aggression
Scale (MOAS), 86
monoamine oxidase inhibitors
(MAOIs), 122
mood activation, 74, 93
mood disorders
characteristics, 90
depressive disorders, 91–3
differentiating between
ADHD and, 70
episodic nature, 70
extremes of mood, 90
potential effect on daily
living, 90
mood disorders in PWS,
90–100
disruptive mood
dysregulation disorder
(DMDD), 97
suicidality and intentional
self-harm, 93–5
see also depressive disorders
in PWS; bipolar
disorders in PWS.
mood reactivity, 92, 122
mood stabilizers, 127–32
carbamazepine and
oxcarbazepine, 129
gabapentin and
pregabalin, 129
lamotrigine, 128
lithium, 128
most commonly utilized,
127–30
overdose, 110
side effects
CNS depression, 130
Steven Johnson’s
Syndrome & Toxic
Epidermal
Necrolysis, 130
Syndrome of
Inappropriate
Antidiuretic Hormone
(SIADH), 132
teratogenic effects, 130
usual dose ranges and,
131
summary of dosages and
side-effects, 131
topiramate, 129
valproic acid (valproate),
100, 128–9, 130
moral development, Kohlberg’s
stages of, 82–3
movement disorders,
as side effect of
antipsychotic
medications, 118–19
multidisciplinary team,
beneficial
disciplines, 24
<table>
<thead>
<tr>
<th>Index</th>
<th>183</th>
</tr>
</thead>
</table>

multiple sleep latency test (MSLT), in evaluation of hypersomnia, 28
muscular spasms (dystonia), 118
mutism, 107
selective, 42,
n-acetyl cysteine (NAC), 61–2, 65
naltrexone, 63, 65, 135
role in managing picking behavior, 62
narcolepsy
associated with a medical condition, 29–30
association with obesity, 30
DSM-5 definition, 29
hallucinations and, 106
ICSD-3 reclassification, 29
management
non-pharmacological, 30
pharmacological, 31, 134
narcolepsy and cataplexy in PWS, 30
therapeutic naps and, 30
type 1 vs type 2, 29
Natalie, case history, 68
National Alliance for Caregiving (NAC), 8
necdin gene deletion, 156
networking, value for reducing risk of caregiver burden and burnout, 13, 20
neurobehavioral manifestations of PWS, 1, 116, 171
final reflections, 167
genetic causes of, 156–7
summary, 165, 167
neurobiological, psychological, and treatment aspects of PWS, 171–3
neurobiology of PWS, 154–67
caregiver note, 167
genetic causes of neurobehavioral problems, 156–7
grey matter abnormalities, 160
hypothalamus, 157–8
neurotransmitter abnormalities, 162–5
response monitoring vs habitual learning & response perseveration, 165–7
white matter abnormalities, 160–2
neuroleptic malignant syndrome (NMS), risk of antipsychotic medication for, 120
neuropsychological evaluations, value for PWS patients, 20
neurotransmitters abnormalities in PWS, 162–5, 171
overview, 155
non-stimulant medications, 134
side effects, 74
Noonan syndrome, 147
norepinephrine, 155, 171
abnormal release of, 162
antidepressant medications and, 121, 122, 123
antipsychotic medications and, 117
possible effects, 155
norepinephrine reuptake inhibitors, ADHD and, 73
nortriptyline, 53, 74, 122
nutritional deficiencies, 70, 118
obesity
 cannabinoid exploration, 135
feature of PWS, 30
hyperphagia and, 1, 30
impact on OSA, 28
JS’s case, 28
management
non-pharmacological, 28
pharmacological, 72
obesity hypoventilation syndrome (OHS), 26
sleep-disordered breathing and, 26, 27
object recognition, 161
obsessive-compulsive and related disorders, 43–4
obsessive-compulsive disorder (OCD), 44
treating with SSRIs, 123
obsessive-compulsive symptoms
 treating with antidepressant medications, 120
treating with antipsychotic medications, 118
obstructive sleep apnea (OSA), 26,
daytime consequences, 27
definition, 27
diagnosis, 27
potential adverse effects of sedating medications, 28
role of weight management in treatment of, 28
serious health consequences, 26
oculogyric crisis, 3, 118
olanzapine, 54, 118, 136
olfactory hallucinations, 106
oppositional behaviors, 43
operant conditioning, 117
changing problem behaviors through, 80–1
opioids, commonly implicated in delirium, 110
opiods, commonly implicated in delirium, 110
oppositional behaviors, 43
orbitofrontal cortex (OFC), 160
olfactory hallucinations, 106
overdose
antidepressants, 110, 125
antipsychotic medications, 120
benzodiazepines, 52
mood stabilizers, 110
TCAs, 53, 122
oxcarbazepine, 62, 129
oxycodone, 110
oxytocin, 54, 135, 156
pain
anxiety disorders and, 53
change and, 30
impaired perception of in PWS, 58
acceptance for in PWS, 43
treating with antidepressant medications, 122, 123
paliperidone, 118
panic attacks, symptoms, 42
panic disorder, 42
paradoxical agitation, 156
benzodiazepines side effect, 52, 134
paranoid thoughts, 3, 111
parents, Nina Roberto’s experience
advocacy, 153
parents, Nina Roberto’s (cont.)
coronavirus pandemic
and, 152
diagnosis of PWS, 147
emotions and behavior, 149–50
hoarding, 151
hyperphagia, 150–1
marital discord and divorce, 151–2
medical challenges, 148–9
‘new normal’, 153
pregnancy, birth and early years, 145–8
setting up a schedule, 152
siblings of the child with PWS, 152
parksinsonism
antipsychotic medications
and, 117
causes, 117, 118
Parkinsson’s disease vs, 118
treatment of, 118
Parksinson’s disease, 30, 118
paroxetine, 52, 123, 125
partial eyelid droop, 30
Patient Health Questionnaire (PHQ-9), 120
Patricia, case history, picking behavior, 58
pediatric neurologists, 19
pediatricians, 19
perceptual disturbance, 111, 117
perseveration, 43
persistent depressive disorder, 92
prevalence in PWS, 92
Pete, case history, bipolar disorder, 98
Peter, case history
anxiety, 43
bedwetting, 43
separation anxiety disorder, 43
phenetermine, 72
phobia, specific, 42
picking (excoriation disorder), 58–9
automatic behavior, 59
behavioral interventions, 60, 61
benefits of SRIs, 52, 62
deficient response monitoring and, 172
definition, 44
hypothalamic dysfunction and, 158
management
non-pharmacological, 60–1
pharmacological, 61–2
mechanical interventions, 61
medical repercussions of untreated picking behavior, 58
pain tolerance in PWS and, 43
Patricia’s case, 58
prevalence in PWS, 44, 59
psychosis and, 108, 114
range of severity, 58
rectal picking, 59, 61
‘self-soothing’ notion, 160
stimulant medications and, 87
surgical procedures and, 60
treating with antidepressant medications, 121
underlying cause, 59
pimavanserin, 163
pitolisant, 31, 134
poor frustration tolerance, 47–8, 53–4
positive parenting strategies, managing aggression with, 84–5
positive reinforcement, managing anxiety with, 50
post-traumatic stress disorder (PTSD), 44
Aisha’s case, 45–6
diagnosis, 45
parents and caregivers, 77
symptoms, 45
treating with SRIs, 123
Prader-Willi Syndrome organizations, 13, 21, 25
prefrontal cortex, 160, 162
pregabalil, 54, 129
Project ECHO, University of New Mexico, 22, 173
prolactin, 119
propranolol, 54, 129
psychiatric illnesses, prevalence in patients with PWS, 116
psychiatrists/psychiatric practitioners/
psychiatry, 19, 20, 21
close supervision of SRI medication, 53
finding, 21, 115
importance in the multidisciplinary team, 24, 94, 140
symptoms prompting evaluation by, 106–7
psychodynamic therapy, 38
psychological assessment/testing, 20, 34
psychopharmacology, 116–140
antidepressant medications, 120–5
antipsychotic medications, 117–20
benzodiazepines, 132–4
caregiver note, 138–140
drug-drug interactions, 120, 135–138
mood stabilizers, 127–32
other medication classes, 134–135
psychosis
changing definition, 103
delusions, 104–5
disorganized or abnormal motor behavior, 107
disorganized thinking (formal thought disorder), 106–7
DSM-5 definition, 104
hallucinations, 105–6
hyperphagia and, 108, 114
negative symptoms, 107
picking and, 108, 114
prevalence in PWS vs the general population, 103
serotonin abnormalities and, 163
stigma surrounding the word, 103
usual presentation, 117
white matter abnormalities and, 162
psychotic disorders
brief psychotic disorder, 111
delirium, 109–11
delusional disorder, 108
DSM-5 classification, 108–11
schizoaffective disorder, 109
schizophrenia, 108–9
schizophreniform disorder, 109
psychotic disorders in PWS, 103–15
caregiver note, 114
cycloid psychosis, 111–13
management
non-pharmacological, 114
pharmacological, 113–14
psychotropic medications, 20
managing bipolar disorders
with, 100
naming conventions, 116
potential impact of sudden
cessation, 23
prevalence of use by patients
with PWS, 116, 121
sleep disturbance and, 28
QTc prolongation, risks of
antipsychotic
medication for, 119
quetiapine, 31, 87, 118
quetiapine
methylphenidate, 63
QuilliChew ER, 72
Quillivant, 72
reactive attachment
disorder, 45
rectal picking, see also picking
(excoriation disorder),
59, 61
residential placement, Amon’s
case, 4
respite care, 10, 11, 12
advantages of agency
providers, 12
response monitoring
concept of, 49, 172
enhancing treatments, 172
habitual learning & response
perseveration vs, 165–7
impact of impairment, 167
improving, 172
impulsivity and, 165, 172
inability to engage in, 160
response monitoring system,
consequences of
reduced functioning, 49
response perseveration
anxiety-related, 48–9
caregiver note, 54
concept of, 48, 172
impulsivity and, 48
potential mechanisms, 160–
164–5, 166–7
underlying mechanism for
anxiety, 48–9
restless legs syndrome, 118
restraint, Alisha’s case, 46
rimonabant, 135
risk-taking behaviors, 90
risperidone
advantages of
prescribing, 118
dosage, 87, 114
dystonia and, 118
managing aggression with,
38, 87
managing anxiety with, 54
managing behavioral
problems with, 117
managing delirium with, 111
side effects, 28
sleep disturbances and, 27
Ritalin, 72
Roberto, Nina, 14, 145
experience as a parent of
a child with PWS,
145–53
Roberto, Nina, experience as
a parent of a child with
PWS
see also parents, Nina
Roberto’s experience;
Sonny, case history.
Schaaf-Yang syndrome, 156
schizoaffective disorder, 109
schizophrenia, 108–9
characteristic symptoms,
108
genetic abnormalities
and, 103
somnolence associated with
risperidone
prescription, 27
typical symptoms in
PWS, 103
white matter abnormalities
and, 161
schizophreniform
disorder, 109
school psychologists, 20
seasonal affective disorder, 93
seizures
benzodiazepines and, 132
risk in PWS, 52
risk of bupropion treatment
for, 124
serotonin syndrome and, 125
treating with sodium
channel blockers, 129
selective mutism, 42
selegiline, 123
self-harm, mood disorders
and, 93–5
semantic cognition, 162
separation anxiety disorder,
41
separation anxiety disorder,
Peter’s case, 43
serotonergic agents, increased
sensitivity to, Amon’s
case, 3, 5
serotonin
abnormalities in PWS,
162–3, 171
impulsivity and, 163
psychosis and, 163
antidepressant medications
and, 121, 122, 123
antipsychotic medications
and, 117
appetite and, 163
and, 125
genetic basis of
modulation, 156
inhibitory nature, 155
interaction with
dopamine, 155
MAOIs and, 122
receptor types, 155
serotonin syndrome, 125
serotonin and norepinephrine
reuptake inhibitors
(SNRIs), 123
ADHD and, 74
side effects, 123
serotonin reuptake inhibitors
(SRIs), 123
examples, 52
hoarding behavior and, 63
limitations for PWS, 5,
52, 172
managing anxiety with,
52–3, 123
managing picking behavior
with, 52, 62
managing PTSD with, 123
mirtazapine and, 124
range of issues addressed
by, 116
risks for suicidality, 53, 62
side effects, 53, 123
trazodone and, 124
serotonin syndrome,
antidepressant
medications and, 125
sertraline, 87, 123
sexual abuse, of adults with intellectual disabilities, 46
siblings of the child with PWS, 152
skin picking, see also picking (excoriation disorder), 26
sleep, importance of good sleep hygiene for caregivers, 12
sleep apnea, 87, 133
sleep disturbances
agitation and aggression in PWS and, 79
caregiver notes, 31
diagnosis, 29–30
insomnia, 31
management
non-pharmacological, 30
pharmacological, 31, 71, 134
narcolepsy and cataplexy in PWS, 30
psychotropic medications and, 28
sleep hygiene, 31
sleep-disordered breathing prevalence in PWS
patients, 26
risk factors for, 26, 27
Snord115 gene cluster, 157
Snord16 gene cluster, 157, 161
social anxiety disorder, 42
social disinhibition, 42, 45
social isolation, 11
social media, 11, 13
sodium oxybate, 31
Sonny, case history
diagnosis of PWS, 147
emo tions and behavior, 149–50
hoarding, 151
hyperphagia, 150–1
medical history, 148–9
siblings, 152
Sophia, case history, delirium, 110–11
spatial memory, white matter abnormalities and, 162
specific phobia, 42
St. John’s Wort, 125, 136
stealing, 43, 64, 82
steroids
commonly implicated in delirium, 110
role of in managing picking behavior, 60
Steven Johnson’s Syndrome, 130
stigma
associated with mental illness, 25
as barrier to seeking professional mental healthcare, 18
stimulant medications, 134
appetite suppression and, 71, 72
benefits for children and adolescents with autism, 39
managing ADHD with, 71–3
managing aggression with, 87
side effects, 72, 73
types, 71, 72
strangers, excessive familiarity with, 42
streamlining services, value for reducing risk of caregiver burden and burnout, 13–14
stroke, incoherent speech and, 107
substance use disorders, 48
suicidal thoughts
caregiver note, 100
norepinephrine reuptake inhibitors and, 74
pharmacological management, 96
suicidality
antidepressant medications and, 96, 125
mood disorders and, 93–5
rarity of in PWS, 97
risks of SRIs for, 53, 62
suicide, risk of caregiver burden for, 9
superior longitudinal fasciculus, 161
superior occipital gyrus, 161
superior temporal gyrus, 162
support groups, 13
surgical procedures, complications due to picking behaviors, 60
Syndrome of Inappropriate Antidiuretic Hormone (SIADH), 132
tantrums, 3, 26, 38, 42, 43, 46, 50, 68
tardive dyskinesia, 118, 119
TCA overdose, 53, 122
telehealth services, 14, 25
tem per, 26, 46, 68
temper outbursts, 87, 97
temporal lobe epilepsy, olfactory hallucinations and, 106
tetra benzine, 119
therapeutic alliance, 20, 22, 23
“Thinking Fast and Slow” (Kahneman), 165
thyroid dysfunction
anxiety and, 41
depression and, 120
tic disorders, 60, 72
topiramate, 62, 65, 129, 130
valproic acid (valproate), 100, 107
Tourette syndrome, 60, 72, 174
Toxic Epidermal Necrolysis, 130
tramad ol, 125
trazodone, 124
trichotillomania (hair-pulling), 44
tricyclic antidepressants, potential role in managing anxiety, 53
triptans, 125
tyramine reaction, antidepressant medications and, 122, 125
uniparental disomy (UPD), see also material
uniparental disomy (mUPD), 2, 5, 34, 43
United States, health system structure, 5
valproic acid (valproate), 100, 128–9, 130
variable mouth opening, 30
vegetative functions, hypothalamic dysfunction and, 158
venlafaxine, 63, 123
viloxazine, 73, 134, 163
Index

violence/violent behavior, 43, 46, 79, 100
vitamin deficiencies, depression and, 120
vitamin E, high dose, 119
weight gain
antidepressant medications and, 122, 124
antipsychotic medications and, 28, 38, 54, 100, 117–18, 119
GABA analogs and, 129
TCAs and, 122
weight loss
antidepressant medications and, 124
bariatric surgery for, 28
GABA agonists and, 129
JS’s case, 28
risk of caregiver burden for, 9
white matter abnormalities, 160–2
role of, 154–5
withdrawal reaction
antidepressant medications, 125
antipsychotic medications, 119
benzodiazepines, 52
www.PsychologyToday.com, 21
ziprasidone, 118